Ferinject in New Zealand: what the latest BPAC and Medsafe guidance says

If you've been told you need an iron infusion in New Zealand, it will almost certainly be ferric carboxymaltose - better known by its brand name, Ferinject. It is the intravenous iron that is funded for community use here, and it's the one we administer at VitalLine. Because it is a prescription medicine, the guidance around who should receive it, and how, comes from trusted national sources: bpac(nz) (the Best Practice Advocacy Centre) and Medsafe, New Zealand's medicines safety authority.

Guidance evolves as more real-world safety data comes in, so here is a plain-English summary of where things currently stand - the same information we base our own screening and consent process on.

What bpac(nz) says about who should have an iron infusion

The bpac(nz) guidance is clear that intravenous iron is not a first-line treatment for most people. Oral iron tablets remain the usual starting point for iron deficiency. An infusion is appropriate when oral iron hasn't worked or isn't tolerated, when iron needs to be restored quickly (for example, later in pregnancy or before surgery), or when a medical condition prevents iron being absorbed through the gut.

That is exactly why every VitalLine iron booking involves a screening review and a prescriber decision before any infusion happens - an infusion should be the right tool for your situation, not a default.

Medsafe's December 2024 update: low phosphate (hypophosphataemia)

The most significant recent safety communication is Medsafe's December 2024 Prescriber Update reminding clinicians that Ferinject can lower blood phosphate levels. This is called hypophosphataemia, and studies suggest it occurs in somewhere between 2% and 27% of people, depending on the group studied.

• For most people it is mild, causes no symptoms, and resolves on its own.
• Occasionally it can be more severe or prolonged - the risk is higher with repeated infusions over time.
• Symptoms to watch for in the weeks after an infusion include ongoing tiredness, bone pain or muscle weakness.
• People having repeated infusions, or who have kidney problems, vitamin D deficiency or malabsorption, may warrant phosphate monitoring through their GP.

This is why our screening asks whether you've had iron infusions before, and why our consent information specifically mentions phosphate - it's current New Zealand guidance, built directly into our process.

Other points from the current guidance

• Common, usually mild effects include headache, nausea and dizziness, and some people notice delayed flu-like symptoms one to two days after the infusion.
• If the medicine leaks outside the vein it can cause long-lasting brown skin staining, which is why your cannula site is monitored throughout.
• Serious allergic reactions are rare - in the order of 1 in 1,000 - but this is why infusions should always be given by clinicians trained and equipped to manage them, with a 30-minute observation period afterwards.

What this means for you

None of this guidance is a reason to avoid an iron infusion when you genuinely need one - untreated iron deficiency has real consequences for energy, cognition and wellbeing. It simply means the decision should be made properly: recent blood results, a screening review, a prescriber's assessment, and informed consent that covers the real risks rather than glossing over them.